Critical care for pediatric asthma: wide care variability and challenges for study
- PMID: 22067984
- PMCID: PMC3298633
- DOI: 10.1097/PCC.0b013e318238b428
Critical care for pediatric asthma: wide care variability and challenges for study
Abstract
Objectives: To describe pediatric severe asthma care, complications, and outcomes to plan for future prospective studies by the Collaborative Pediatric Critical Care Research Network.
Design: Retrospective cohort study.
Setting: : Pediatric intensive care units in the United States that submit administrative data to the Pediatric Health Information System.
Patients: Children 1-18 yrs old treated in a Pediatric Health Information System pediatric intensive care unit for asthma during 2004-2008.
Interventions: None.
Measurements and main results: Thirteen-thousand five-hundred fifty-two children were studied; 2,812 (21%) were treated in a Collaborative Pediatric Critical Care Research Network and 10,740 (79%) were treated in a non-Collaborative Pediatric Critical Care Research Network pediatric intensive care unit. Medication use in individual Collaborative Pediatric Critical Care Research Network centers differed widely: ipratropium bromide (41%-84%), terbutaline (11%-74%), magnesium sulfate (23%-64%), and methylxanthines (0%-46%). Complications including pneumothorax (0%-0.6%), cardiac arrest (0.2%-2%), and aspiration (0.2%-2%) were rare. Overall use of medical therapies and complications at Collaborative Pediatric Critical Care Research Network centers were representative of pediatric asthma care at non-Collaborative Pediatric Critical Care Research Network pediatric intensive care units. Median length of pediatric intensive care unit stay at Collaborative Pediatric Critical Care Research Network centers was 1 to 2 days and death was rare (0.1%-3%). Ten percent of children treated at Collaborative Pediatric Critical Care Research Network centers received invasive mechanical ventilation compared to 12% at non-Collaborative Pediatric Critical Care Research Network centers. Overall 44% of patients who received invasive mechanical ventilation were intubated in the pediatric intensive care unit. Children intubated outside the pediatric intensive care unit had significantly shorter median ventilation days (1 vs. 3), pediatric intensive care unit days (2 vs. 4), and hospital days (4 vs. 7) compared to those intubated in the pediatric intensive care unit. Among children who received mechanical respiratory support, significantly more (41% vs. 25%) were treated with noninvasive ventilation and significantly fewer (41% vs. 58%) were intubated before pediatric intensive care unit care when treated in a Pediatric Health Information System hospital emergency department.
Conclusions: Marked variations in medication therapies and mechanical support exist. Death and other complications were rare. More than half of patients treated with mechanical ventilation were intubated before pediatric intensive care unit care. Site of respiratory mechanical support initiation was associated with length of stay.
Conflict of interest statement
References
-
- Moorman JE, Rudd RA, Johnson CA, et al. National Surveillance for Asthma --- United States, 1980—2004. MMWR. 2007 Oct 19;56(SS08):1–14. 18–54. - PubMed
-
- Hartman ME, Linde-Zwirble WT, Angus DC, Watson RS. Trends in admissions for pediatric status asthmaticus in New Jersey over a 15-year period. Pediatrics. 2010;126:e904–911. - PubMed
-
- Expert Panel Report 3 (EPR3) Guidelines for the Diagnosis and Management of Asthma. [Oct 2, 2010]; MANAGING EXACERBATIONS OF ASTHMA available at: http://www.nhlbi.nih.gov/guidelines/asthma/11_sec5_exacerb.pdf. - PubMed
-
- Management of asthma exacerbation in acute care settings. [Oct 2, 2010];GINA at a glance management reference. http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId=1920.
-
- Ducharme FM, Zemek RL, Chalut D, et al. Written action plan in pediatric emergency room improves asthma prescribing, adherence and control. Am J Respir Crit Care Med. 2011;183:195–203. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U10HD049945/HD/NICHD NIH HHS/United States
- U01HD049934/HD/NICHD NIH HHS/United States
- U10 HD050012/HD/NICHD NIH HHS/United States
- U10 HD049945/HD/NICHD NIH HHS/United States
- U10HD049981/HD/NICHD NIH HHS/United States
- UG1 HD050096/HD/NICHD NIH HHS/United States
- U10 HD049981/HD/NICHD NIH HHS/United States
- U10 HD050096/HD/NICHD NIH HHS/United States
- U10 HD049983/HD/NICHD NIH HHS/United States
- UG1 HD063108/HD/NICHD NIH HHS/United States
- RL1 HD107773/HD/NICHD NIH HHS/United States
- U10HD050096/HD/NICHD NIH HHS/United States
- U10HD049983/HD/NICHD NIH HHS/United States
- U10HD050012/HD/NICHD NIH HHS/United States
- U01 HD049934/HD/NICHD NIH HHS/United States
- U10HD500009/HD/NICHD NIH HHS/United States